Fmr LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,970,338 shares of the biopharmaceutical company’s stock after buying an additional 3,958,324 shares during the period. Fmr LLC owned about 0.36% of Pfizer worth $713,596,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in PFE. Fusion Family Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $109,000. First National Bank Sioux Falls increased its position in shares of Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,750 shares during the period. Cornerstone Advisors Inc. increased its position in shares of Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 541 shares during the period. Gierl Augustine Investment Management Inc increased its position in shares of Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares during the period. Finally, Stanford Investment Group Inc. increased its position in shares of Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 456 shares during the period. 69.53% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE:PFE) opened at 34.38 on Tuesday. The company has a 50-day moving average of $33.34 and a 200-day moving average of $32.84. Pfizer Inc. has a 1-year low of $29.17 and a 1-year high of $37.39. The company has a market cap of $204.63 billion, a PE ratio of 29.31 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $13.60 billion for the quarter, compared to analyst estimates of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 EPS. Equities analysts forecast that Pfizer Inc. will post $2.55 EPS for the current year.
Your IP Address:
PFE has been the topic of several recent analyst reports. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, December 2nd. They issued a “neutral” rating on the stock. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Tuesday, January 3rd. Barclays PLC set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, March 16th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.47 target price on the stock. in a report on Monday, February 6th. Finally, Jefferies Group LLC set a $34.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Friday, February 17th. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $37.32.
In other news, insider Rady A. Johnson sold 4,500 shares of the firm’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $34.19, for a total transaction of $153,855.00. Following the completion of the sale, the insider now owns 54,963 shares in the company, valued at approximately $1,879,184.97. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mikael Dolsten sold 30,970 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $34.51, for a total transaction of $1,068,774.70. Following the sale, the insider now owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,470 shares of company stock valued at $2,449,150. 0.07% of the stock is currently owned by corporate insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.